Prehospital stroke care: potential, pitfalls, and future
Prehospital stroke care: potential, pitfalls, and future
复制标题
DOI：
10.1097/wco.0b013e328334dafb
复制
发表时间：
2010-02-01
影响因子：
4.8
通讯作者：
Amarenco, Pierre
中科院分区：
文献类型：
--
作者：
Mazighi, Mikael;Derex, Laurent;Amarenco, Pierre
综述目的组织型纤溶酶原激活剂是唯一获准用于急性缺血性中风的药物治疗方法，但仅用于不到5%的患者。过度的院前和院内延误以及卒中中心覆盖率的缺乏是对卒中护理产生负面影响的主要问题。新的策略正在开发和评估，以增加组织型纤溶酶原激活剂治疗的patients.Recent findingsFactors，限制快速获得急性中风护理进行了讨论，包括那些影响时间间隔从中风发作到入院。我们还描述了有希望减少院前延误和增加获得急性中风treatment.SummaryThe缩短院前延误的策略，需要患者和卫生专业人员的教育和运输策略的优化。未来的发展可能包括视频会议，提供远程中风的专业知识，战略（即治疗干预），可能有助于治疗急性中风患者与组织型纤溶酶原激活剂，和院前选择候选人血管内治疗。
Purpose of reviewTissue-type plasminogen activator is the only pharmacological treatment approved for acute ischemic strokes but is administered to less than 5% of the patients. Excessive prehospital and in-hospital delays and lack of stroke center coverage are major issues that negatively impact stroke care. New strategies are being developed and evaluated to increase the number of tissue-type plasminogen activator-treated patients.Recent findingsFactors that limit rapid access to acute stroke care are discussed, including those influencing time intervals from stroke onset to hospital admission. We also describe strategies that hold promise to reduce prehospital delays and increase access to acute stroke treatment.SummaryThe shortening of prehospital delays requires education of patients and health professionals and optimization of transport strategies. Future developments may include video conferencing offering telestroke expertise, strategies (i.e. therapeutic interventions) that might help to treat acute stroke patients with tissue-type plasminogen activator, and prehospital selection of candidates for endovascular therapies.